Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,578 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Factors Associated With Severity of COVID-19 Disease in a Multicenter Cohort of People With HIV in the United States, March-December 2020.
Shapiro AE, Bender Ignacio RA, Whitney BM, Delaney JA, Nance RM, Bamford L, Wooten D, Keruly JC, Burkholder G, Napravnik S, Mayer KH, Webel AR, Kim HN, Van Rompaey SE, Christopoulos K, Jacobson J, Karris M, Smith D, Johnson MO, Willig A, Eron JJ, Hunt P, Moore RD, Saag MS, Mathews WC, Crane HM, Cachay ER, Kitahata MM; CFAR Network of Integrated Clinical Systems. Shapiro AE, et al. Among authors: jacobson j. J Acquir Immune Defic Syndr. 2022 Aug 1;90(4):369-376. doi: 10.1097/QAI.0000000000002989. J Acquir Immune Defic Syndr. 2022. PMID: 35364600 Free PMC article.
Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068.
Jacobson JM, Pat Bucy R, Spritzler J, Saag MS, Eron JJ Jr, Coombs RW, Wang R, Fox L, Johnson VA, Cu-Uvin S, Cohn SE, Mildvan D, O'Neill D, Janik J, Purdue L, O'Connor DK, Vita CD, Frank I; National Institute of Allergy and Infectious Diseases-AIDS Clinical Trials Group 5068 Protocol Team. Jacobson JM, et al. J Infect Dis. 2006 Sep 1;194(5):623-32. doi: 10.1086/506364. Epub 2006 Aug 1. J Infect Dis. 2006. PMID: 16897661 Clinical Trial.
No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy.
Gandhi RT, Coombs RW, Chan ES, Bosch RJ, Zheng L, Margolis DM, Read S, Kallungal B, Chang M, Goecker EA, Wiegand A, Kearney M, Jacobson JM, D'Aquila R, Lederman MM, Mellors JW, Eron JJ; AIDS Clinical Trials Group (ACTG) A5244 Team. Gandhi RT, et al. Among authors: jacobson jm. J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):229-35. doi: 10.1097/QAI.0b013e31823fd1f2. J Acquir Immune Defic Syndr. 2012. PMID: 22083073 Free PMC article. Clinical Trial.
Establishment, retention, and loss to follow-up in outpatient HIV care.
Fleishman JA, Yehia BR, Moore RD, Korthuis PT, Gebo KA; HIV Research Network. Fleishman JA, et al. J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):249-59. doi: 10.1097/QAI.0b013e318258c696. J Acquir Immune Defic Syndr. 2012. PMID: 22531758 Free PMC article.
Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial.
Rodriguez B, Asmuth DM, Matining RM, Spritzler J, Jacobson JM, Mailliard RB, Li XD, Martinez AI, Tenorio AR, Lori F, Lisziewicz J, Yesmin S, Rinaldo CR, Pollard RB. Rodriguez B, et al. Among authors: jacobson jm. J Acquir Immune Defic Syndr. 2013 Dec 1;64(4):351-9. doi: 10.1097/QAI.0b013e3182a99590. J Acquir Immune Defic Syndr. 2013. PMID: 24169120 Free PMC article. Clinical Trial.
2,578 results